Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ophthotech Corp (NASDAQ:OPHT)

2.89
Delayed Data
As of Dec 08
 -0.10 / -3.34%
Today’s Change
2.24
Today|||52-Week Range
40.34
-40.17%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$104.2M

Company Description

Ophthotech Corp. operates as a biopharmaceutical company. It focuses on discovering, developing and commercializing novel therapeutics to treat diseases of the back of the eye. It develops therapies for age-related macular degeneration. Its product candidates include Fovista Anti platelet derived growth factor Therapy, Zimura Anti-Complement and Aptamer Technology. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.

Contact Information

Ophthotech Corp.
One Penn Plaza
New York New York 10119
P:(212) 845-8200
Investor Relations:
(212) 845-8231

Employees

Shareholders

Other institutional53.02%
Individual stakeholders36.31%
Mutual fund holders10.58%

Top Executives

Glenn P. SblendorioPresident & Chief Executive Officer
Keith WestbyChief Operating Officer & Senior Vice President
David F. CarrollChief Financial Officer & Treasurer
Barbara A. WoodSecretary, Senior Vice President & General Counsel
Evelyn M. HarrisonChief Clinical Operations Officer